This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Getty Images milla1cf Tue, 04/30/2024 - 12:56 April 30, 2024 — A multicenter study led by Vanderbilt University Medical Center ( VUMC ) and Lipscomb University College of Pharmacy in Nashville has identified a potential new treatment for acute heartfailure , a leading cause of hospitalization and death. hospitals from emergency rooms.
However, researchers said the drug may be helpful in reducing heartfailure risks, including hospitalization, following a heart attack. SGLT-2 inhibitors were initially approved to treat Type 2 diabetes by lowering blood sugar. About 32% had Type 2 diabetes.
While composite of death and heartfailure hospitalizations was not significantly reduced, empagliflozin may help reduce heartfailure risks after a heart attack, according to results from the EMPACT-MI trial presented on day one of the American College of Cardiology Scientific Sessions, ACC.24,
Introduction This study aimed to evaluate the use and dose of loop diuretics (LDs) across the entire ejection fraction (EF) spectrum in a large, ‘real-world’ cohort of chronic heartfailure (HF) patients. Data regarding daily diuretic dose were stratified by furosemide dose equivalent (FDE)>80 mg or ≤80 mg.
Aims Identifying clinical and echocardiographic parameters associated with improvement in systolic function in outpatients with heartfailure with reduced ejection fraction (HFrEF) could lead to more targeted treatment improving systolic function and outcome. Beta-coefficients (β-coef) are standardised. to 7.51, p=0.006).
Abstract Diagnosing heartfailure is often difficult due to the non-specific nature of symptoms, which can be caused by a range of medical conditions. Natriuretic peptides (NPs) have been recognized as important biomarkers for diagnosing heartfailure. Use of this acronym would enable the early diagnosis of heartfailure.
Background:Patients with type 2 diabetes are at risk of heartfailure hospitalization. Accounting for all-cause mortality, we obtained the incidence for heartfailure hospitalization at 5 years follow-up; overall and in each SDI group. and 0.80, respectively). and 0.80, respectively).
Introduction:European, American and UK guidelines all endorse the prescription of the 'four pillars' of treatment (ACE/ARBs, b-blockers, MRAs and SGLT2 inhibitors) for heartfailure with reduced LV systolic function (HFrEF). Many doctors believe that it is difficult to initiate and maintain patients on all these medications.
Background:The current AHA stroke prevention guidelines give Class 1 recommendations that patients with AIS and diabetes should receive glucose-lowering agents with cardiovascular benefit to reduce risk of MACE. Patients were identified to have diabetes as derived by the Charlson Comorbidity Index ICD 10 codes E10 through E14.
Methods We used the Swedish Registry of Cardiopulmonary Resuscitation, merged with the Inpatient Registry and Outpatient Registry to identify patients with OHCA from 2010 to 2020 and to collect all their comorbidities as well as discharge diagnoses (among those admitted to hospital). had type 2 diabetes, compared with 19.6% of the men.
Methods From November 2022 to May 2024, we conducted an outpatient follow-up of 41 patients receiving WCD. Among the cohort, 54% had hypertension, 41% were smokers and 66% had dyslipidaemia, while 27% were diabetic. In this study, we explore the use of WCD and evaluate arrhythmic events through comprehensive monitoring.
METHODS:The J-HOP study enrolled outpatients with ≥1 cardiovascular risk factor between 2005 and 2012, with follow-up until March 2015 and extended follow-up from December 2017 to May 2018. Findings were similar in the subgroup of high-risk patients (those with diabetes or stroke history).CONCLUSIONS:These
Medical history: History of Ischemic Heart Disease History of Congestive HeartFailureDiabetes Mellitus requiring treatment with insulin Pre-operative serum creatinine >2 mg/dL He had this ECG recorded: What do you think? This patient presented with complications of his dialysis fistula.
Higher troponin correlated with more history of heartfailure, diabetes, and hypertension, as well as higher D-dimer, and nearly all inflammatory markers. Median age was 66.4 were over age 70, and 60% were men. CV disease was more prevalent in those with higher troponin.
Adjusted analyses (Cox proportional hazard ratios) illustrate a higher risk of heartfailure hospitalization (HFH) and all-cause mortality (ACM) after a median follow-up of 18months in patients with heartfailure and iron deficiency (ID) as assessed by transferrin saturation (TSAT) <20% and iron 13 mol/L.
Background Heartfailure (HF), type 2 diabetes (T2D) and chronic kidney disease (CKD) commonly coexist. Inpatient and outpatient healthcare utilisation rates were highest in CKD and HF, and lowest in CKD and T2D. We studied characteristics, prognosis and healthcare utilisation of individuals with two of these conditions.
1.378]), and heartfailure (1.282 [95%CI, 1.25‐1.315]).ConclusionPatient 1.378]), and heartfailure (1.282 [95%CI, 1.25‐1.315]).ConclusionPatient ConclusionPatient discharge disposition and comorbidities are driving factors in 90‐day readmissions following an ischemic stroke and differ from 30‐day readmissions.
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content